The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia

NCT02844322 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Waldenström Macroglobulinemia

Interventions

DRUG: Bortezomib
DRUG: Rituximab

Sponsor

Institute of Hematology & Blood Diseases Hospital, China